VNOV VitaNova Life Sciences Corp

Overview and Growth

Fiscal 2026 results for VitaNova Life Sciences Corp combined $3.03M of revenue with net loss of $37.30K and an operating cash inflow of $814.41K. The $3.03M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. The top line expanded 13.7% from $2.66M in fiscal 2025, increasing the company’s operating scale. Total assets stood at $2.45M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. Asset turnover was 1.24x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

Gross profit was $910.59K, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. The gross-profit relationship equaled 30.1% of revenue, quantifying the portion retained before operating expenses were recognized. The reported operating result was $3.60K, capturing profitability after direct costs and the operating expenses reflected in the statements. Relative to revenue, operating income represented 0.1%, showing how efficiently sales converted into operating profit. The company ended the period with a net loss of $37.30K, extending the operating result through all remaining items. Net margin was -1.2%, reflecting a loss equal to 1.2% of reported revenue. Pretax income was $6.58K, isolating the reported earnings outcome before the income-tax provision recognized for the fiscal year. Measured against revenue, pretax income equaled 0.2%, adding a pre-tax profitability layer between revenue and net income. The company recognized $43.88K of income tax for the period, completing the transition from pretax income to net income. The income-tax provision equaled 666.8% of pretax income, showing the tax burden absorbed by the year’s earnings. The loss-to-equity relationship was 1.8%, placing the bottom-line deficit against shareholder capital. The net loss equaled 1.5% of period-end assets, showing the deficit relative to the asset base. The company moved from fiscal 2025 net income of $850.75K to a current net loss of $37.30K.

Liquidity and Capital Structure

The company held $2.45M of assets against $395.78K of liabilities and $2.05M of equity, revealing how the asset base was financed. Current assets were $2.43M against $395.78K of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. Current assets covered current liabilities by 6.14x, leaving a positive buffer for near-term obligations. Reported cash and equivalents were $1.60M, separating immediately recognizable cash resources from the rest of the current-asset base. Cash and equivalents represented 403.6% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. The equity-to-assets relationship was 83.8%, placing book capital against the total resource base. Liabilities represented 16.2% of total assets, quantifying the liability-funded share of the company’s resource base. The cash-to-assets relationship was 65.3%, comparing reported cash and equivalents with the full positive asset balance. Compared with $2.26M in fiscal 2025, the current asset base moved 8.4% and finished higher. Against $1.91M of equity in fiscal 2025, the current book-equity balance moved 7.4% and ended higher. Cash and equivalents were 104.0% higher than fiscal 2025 cash of $782.81K, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

Operating activities produced a cash inflow of $814.41K, giving the cash-flow counterpart to the accrual-based profit measures reported for the year. Operating cash flow of $814.41K finished above fiscal 2025 operating cash flow of $192.77K, showing the year-over-year direction of cash generation.

Based on the annual report for the fiscal year ending Apr 30, 2026. Analysis generated Oct 26, 2026.